TERIPARATIDE | A208569 | TEVA PHARMACEUTICALS USA INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Eli Lilly and Company FDA-2016-P-2515 · 27 docket documents Eli Lilly and Company filed this citizen petition on August 18, 2016, requesting that the FDA refuse to approve any abbreviated new drug application (ANDA) citing Forteo (teriparatide injection) as the reference listed drug, including ANDA No. 208569 submitted by Teva Pharmaceuticals USA Inc., and i | 505(q) | 2016-08-23 | Denied | Eli Lilly and Company |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$536.55
per ml
Lowest NADAC/Unit
$536.55
per ml
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00093110616TERIPARATIDE 560 MCG/2.24 ML PEN | $536.55 | ML | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.